title: Symptom-triggered therapy for alcohol withdrawal syndrome in medical inpatients.
abstract: OBJECTIVE
  To assess the efficacy of symptom-triggered therapy vs usual care for alcohol withdrawal syndrome (AWS) in medical inpatients.
  
  
  METHODS
  This study was a retrospective analysis of patients admitted to general medical services between January 1, 1995, and December 31, 1998, who experienced AWS during the admission. This study was conducted at Saint Marys Hospital, Rochester, Minn. Patients were identified from hospital discharge diagnoses and pharmacy data. Symptom-triggered therapy for AWS was initiated in 1997. Patients were divided into preimplementation (1995-1996) and postimplementation (1997-1998) cohorts. Age, sex, medical comorbid conditions, previous AWS (including seizures and delirium tremens), duration of treatment for AWS, benzodiazepine use and dose, complications of AWS, and adverse outcomes of treatment during the incident admission were abstracted from the medical records of eligible patients. Comorbid conditions were classified according to the Charlson comorbidity index. Differences between the cohorts were assessed with use of logistic regression models and analysis of covariance.
  
  
  RESULTS
  Review of medical records from 638 admissions (536 patients) yielded 216 admissions eligible for this study. After adjustment for age, sex, Charlson comorbidity index, previous AWS, previous alcohol withdrawal seizures, and previous delirium tremens, we found no significant difference between cohorts for duration of treatment (P=.16), benzodiazepine use (P=.21), total dose of benzodiazepine (P=.38), or total complication rate (P=.053). We did observe a significant difference in the occurrence of delirium tremens between the 2 treatment groups (P=.04). This was especially apparent for patients with no history of delirium tremens.
  
  
  CONCLUSIONS
  Symptom-triggered therapy is effective treatment for AWS in medical inpatients. In this retrospective study, it did not result in shorter duration of treatment but was associated with a decreased occurrence of delirium tremens, the most severe and life-threatening complication of AWS. This result was most apparent in patients with no history of delirium tremens.
authors.affiliation: Division of Community Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA.
authors.forename: T M
authors.initials: TM
authors.lastname: Jaeger
authors.forename: R H
authors.initials: RH
authors.lastname: Lohr
authors.forename: V S
authors.initials: VS
authors.lastname: Pankratz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000430:Alcohol Withdrawal Delirium / Q000150:complications / Q000188:drug therapy* / Q000451:nursing; D020270:Alcohol Withdrawal Seizures / Q000150:complications / Q000188:drug therapy* / Q000451:nursing; D000704:Analysis of Variance; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001569:Benzodiazepines; D002985:Clinical Protocols; D015897:Comorbidity; D004334:Drug Administration Schedule; D016903:Drug Monitoring / Q000379:methods* / Q000451:nursing / Q000592:standards; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009730:Nursing Assessment / Q000379:methods; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D014151:Anti-Anxiety Agents; D001569:Benzodiazepines